Development of a novel ligand that activates JAK2/STAT5 signaling through a heterodimer of prolactin receptor and growth hormone receptor.

@article{Langenheim2009DevelopmentOA,
  title={Development of a novel ligand that activates JAK2/STAT5 signaling through a heterodimer of prolactin receptor and growth hormone receptor.},
  author={John Fairbanks Langenheim and Wen Yuan Chen},
  journal={Journal of receptor and signal transduction research},
  year={2009},
  volume={29 2},
  pages={
          107-12
        }
}
The objective of this study was to determine if a functional heterodimer of prolactin receptor (PRLR) and growth hormone receptor (GHR) can be formed in humans. A novel ligand was designed that is composed of a GHR antagonist (B2036) and a PRLR antagonist (G129R) fused in tandem (B2036-G129R). Because both B2036 and G129R are binding site 2 inactive antagonists, the B2036-G129R fusion protein, in theory contains only two functional binding site 1s: one for GHR and one for PRLR. We examined the… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 44 REFERENCES

Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule

BC Cunningham, M Ultsch, +3 authors JA. Wells
  • Science
  • 1991
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Presence of the two growth hormone receptor messenger RNA isoforms in human breast cancer.

  • Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research
  • 1995
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

The X-ray structure of a growth hormone-prolactin receptor complex

W Somers, M Ultsch, AM De Vos, AA. Kossiakoff
  • Nature
  • 1994
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL